SCHEMBL15071067

SCHEMBL15071067

COC(=O)C1(c2nc3c(OC)cccn3n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 19/20 0.52
PDE4A P27815 2/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16339826 0.89 PDE4D (0.54) PDE4DPDE4A
SCHEMBL508584 0.88 PDE4D (0.55) PDE4DPDE4APDE4BPDE4C
SCHEMBL3469602 0.88 PDE4A (0.52) PDE4DPDE4A
SCHEMBL15071014 0.79 PDE4D (0.56) PDE4DPDE4APDE4BPDE4C
SCHEMBL509404 0.77 PDE4D (0.53) PDE4DPDE4A
SCHEMBL509295 0.76 PDE4D (0.43) PDE4DPDE4A
SCHEMBL16339827 0.76 JAK2 (0.40)
SCHEMBL509408 0.75 JAK2 (0.45) PDE4DPDE4A
SCHEMBL508512 0.74 KCNA3 (0.43) PDE4D
SCHEMBL509403 0.74 PKM (0.44) PDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794603-B1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-06-15 EP disclosed
US-9181248-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-11-10 US disclosed
US-9181248-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-11-10 US disclosed
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2015-04-16 US disclosed
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2015-04-16 US disclosed
US-8940761-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-01-27 US disclosed
US-8940761-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-01-27 US disclosed
WO-2014206903-A1 METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES LEO PHARMA A/S (DK) 2014-12-31 WO disclosed
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2014-11-06 US disclosed
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2014-11-06 US disclosed
WO-2013092739-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE2A PDE4D 7/4885PDE4A 1/4885PDE4B 6/4885
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE2A PDE4D 7/4885PDE4A 1/4885PDE4B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.